The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers.
 
Karisa Schreck
Honoraria - Novartis
Consulting or Advisory Role - Advarra; Nurix
Research Funding - Springworks Therapeutics (Inst)
(OPTIONAL) Uncompensated Relationships - Fore Biotherapeutics
 
Macarena De La Fuente
Honoraria - Medscape
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); Anheart Therapeutics; Fore Biotherapeutics; Genentech (I); Regeneron (I); Rigel; SERVIER
Research Funding - ADC Therapeutics (I); BeiGene (I); Genentech (I)
(OPTIONAL) Uncompensated Relationships - Society for Neuro-Oncology
 
Jessica Rine
Employment - Fore Biotherapeutics
Stock and Other Ownership Interests - Fore Biotherapeutics
 
Irina Kline
Employment - Fore Biotherapeutics
Stock and Other Ownership Interests - Fore Biotherapeutics
 
Stacie Shephard
Employment - Fore Biotherapeutics
Stock and Other Ownership Interests - Fore Biotherapeutics
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Eric Sherman
Consulting or Advisory Role - AffyImmune Therapeutics; Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - Fore Biotherapeutics (Inst); HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst)
 
Rona Yaeger
Consulting or Advisory Role - Loxo@Lilly; Mirati Therapeutics; Revolution Medicines
Research Funding - Boehringer Ingelheim (Inst); Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)